Chardan Capital Reiterates Buy on Coya Therapeutics, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Coya Therapeutics (NASDAQ:COYA) and maintained an $11 price target.
July 18, 2023 | 8:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated a 'Buy' rating on Coya Therapeutics and maintained an $11 price target.
The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Coya Therapeutics. The maintained price target of $11 suggests that the analyst believes the stock has potential for growth. This could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100